On June 24 & June 25, Axinn partners Aziz Burgy and Chad Landmon spoke at the American Conference Institute’s 10th Annual Summit on Biosimilars Conference in New York. Aziz participated in the panel entitled, "Challenging Patents on Reference Drugs at the PTAB in the Age of Reform" on June 24. Chad participated in the panel entitled, "Naming, Labeling and Marketing Biosimilars: Overcoming Inherent Barriers to Break into the U.S. Marketplace" on June 25.
This two-day event promoted the discussion of the future of biosimilars and formulate solutions to the complex regulatory and patent challenges ahead with industry leaders from both innovator and biosimilar companies.